Last €470.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
RHPP On Other Exchanges
EN Paris
EN Paris
New York
EN Paris
As of 11:50 AM 06/16/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

54, Rue La Boétie

Paris, 75008


Phone: 33 1 53 77 40 00


ough multiple channels, including physicians, pharmacies, hospitals, private companies and distributors in the private sector, and governmental entities and non-governmental organizations in the public and international donor markets, respectively. The company’s Animal Health products are sold and distributed through various channels, depending on each country's legislation for veterinary products. Merial takes into account each country's specific characteristics and sells either to veterinaries, chemists, or via wholesalers. In the case of epizootics, Merial delivers directly to governments. Research and Development Expenditures on research and development amounted to €4,770 million in 2013, comprising €4,087 million in the Pharmaceuticals segment, €518 million in Human Vaccines segment and €165 million in Animal Health segment. Strategy The company executes its strategy along four prongs: growing a global healthcare leader with synergistic platforms; bringing innovative products to market; seizing value enhancing growth opportunities; and adapting its structure for future opportunities and challenges. In May 2014, Sanofi Pasteur, the vaccines division of Sanofi, announced that its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India, has received prequalification status from the World Health Organization (WHO). Competition The company’s prescription drugs compete in all major markets against patented drugs from major pharmaceutical companies such as: Novo Nordisk and Merck in diabetes; Eli Lilly in diabetes and oncology; Bristol-Myers Squibb in oncology; GlaxoSmithKline in thrombosis and oncology; Novartis in diabetes, multiple sclerosis, thrombosis and oncology; Shire in rare diseases and renal; Pfizer in rare diseases and oncology; Biogen Idec, Teva and Merck Serono in multiple sclerosis; Bayer in multiple sclerosis and thrombosis prevention; Roche in oncology; Johnson & Johnson in oncology and thrombosis prevention; AstraZeneca in cardiovascular diseases and oncology; Boehringer-Ingelheim in diabetes and thrombosis; and Fresenius Medical Care in renal diseases. The company’s CHC business competes with multinational corporations such as Johnson & Johnson, Bayer, Pfizer, Novartis, and GlaxoSmithKline. The company’s generics business competes with multinational corporations such as Teva, Sandoz (a division of Novartis), Mylan and Actavis and local players, especially in emerging markets. In its Human Vaccines business, the company competes primarily with multinational players backed by large healthcare groups, including Merck (outside Europe), GlaxoSmithKline, Pfizer (Wyeth), Novartis and Johnson & Johnson (Crucell). In specific market segments, Sanofi Pasteur competes with mid-size international players (such as CSL of Australia in the influenza market for the Southern Hemisphere). In its Animal Health business, the company competes primarily with international companies like Zoetis, Merck and Elanco in both production and companion animals; with Boehringer Ingelheim in production animals; with Boehringer Ingelheim mainly in the vaccines segment; with Novartis and Bayer for pets, particularly for parasiticides; and with Virbac, Ceva and Vetoquinol, French companies with global presence, for pharmaceuticals and/or vaccines. Significant Events In May 2014, Global Green Inc. announced the 90-day extension of an existing agreement with Merial Ltd., the Animal Health Division of Sanofi. In May 2014, Sanofi signed an agreement with the regional government of Puglia in Italy a deal worth EUR 8.4 million for the expansion of the company's plant in Brindisi to enable the production of antibiotics. In June 2014, CQDM and Sanofi Canada announced their partnership to support highly innovative research in Quebec and Canada. In August 2014, Sanofi and MannKind have signed an exclusive licensing agreement to develop and commercialise Afrezza (insulin human) inhalation powder. In August 2014, Illumina, Inc. announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a univer


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €470.00 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.27 USD +0.44
Amgen Inc $159.97 USD +0.24
Bayer AG €128.12 EUR -1.39
Bristol-Myers Squibb Co $62.02 USD -0.445
GlaxoSmithKline PLC 1,484 GBp -14.50
View Industry Companies

Industry Analysis


Industry Average

Valuation RHPP Industry Range
Price/Earnings 23.9x
Price/Sales 2.9x
Price/Book 1.9x
Price/Cash Flow 14.7x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at